[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurosurgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurosurgery":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,79,103,137,168,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100628955","real-time-craniotomy-planning-using-mixed-reality-100628955",false,"NCT07468370","Real Time Craniotomy Planning Using Mixed Reality","Investigation of Augmented Reality\u002FMixed Reality Viewer for Surgical Planning in Cranial Surgery","Brain Tumor Group Inclusion Criteria:\n\n* Diagnosis: Patients diagnosed with a brain tumor requiring surgical intervention.\n* Age: Adults aged 18 years and older.\n* Consent: Patients who are able to provide written informed consent and are willing to comply with study procedures.\n* Preoperative Imaging: Patients who have undergone standard of care preoperative imaging (e.g., MRI, CT) suitable for use with the Brainlab Mixed Reality Viewer.\n* Surgical Eligibility: Patients deemed eligible for craniotomy based on current clinical standards and the judgment of the attending neurosurgeon.\n\nBrain Tumor Group Exclusion Criteria:\n\n* Inability to Provide Informed Consent: Subject is unable to provide written informed consent due to cognitive impairment, language barriers, or other reasons that preclude them from understanding the study's requirements.\n* Emergency Surgery: Subject requires emergency craniotomy where there is insufficient time to perform preoperative planning with the Mixed Reality Viewer.\n* Concurrent Participation in Other Clinical Trials: Subject is currently enrolled in another clinical trial that could interfere with the results of this study or place additional burdens on the subject.\n* Unstable Clinical Condition: Subject has a medical condition that is unstable or severe enough to preclude safe participation in the study, as determined by the investigator (e.g., severe cardiac or respiratory conditions).\n\nSurvey Group Inclusion Criteria:\n\n* Hospital Personnel: Includes hospital personnel operating or assisting in the brain tumor resection surgeries where the study device is being utilized on an enrolled subject in the study. This includes the Investigators, Clinical Research Coordinator, OR Nurses, and Residents.\n* Age: Adults aged 18 years and older.\n* Consent: Hospital personnel who are able to provide written informed consent and are willing to complete the survey.\n\nSurvey Group Exclusion Criteria:\n\n* Inability to Provide Informed Consent: Hospital personnel is unable to provide written informed consent","ALL","18 Years",{"count":19,"type":20},54,"ESTIMATED","OBSERVATIONAL","This study is a prospective observational study designed to evaluate the effectiveness of Brainlab's Mixed Reality Viewer in enhancing the accuracy and efficiency of preoperative craniotomy planning. The study will be conducted at a single site with two enrollment groups. Group 1 has a target enrollment of 38 subjects. Group 2 has a target enrollment of 16 subjects. By observing the device's use during standard surgical procedures, we can accurately measure its impact on incision planning accuracy, time efficiency, and overall ease of use compared to traditional neuronavigation systems. This design allows for the collection of both quantitative and qualitative data, providing a robust assessment of the Mixed Reality Viewer's potential to enhance surgical outcome",[24,25,26,27],"Neurosurgery","Surgical Planning","Brain Tumor Adult","Craniotomy Tumor Removal Surgery",[29,30,31],"mixed reality","craniotomy planning","tumor localization","NOT_YET_RECRUITING","2026-03-11",{"date":35,"type":36},"2026-03-12","ACTUAL",{"date":38,"type":20},"2026-06",{"date":40,"type":20},"2027-06",{"name":42,"class":43},"Brainlab AG","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100623548","dexmedetomidine-for-postoperative-analgesia-and-delirium-prevention-after-neurosurgery-dex-neuro-trial-100623548","NCT07398066","DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial)","DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery: A Double-blinded Randomised Placebo-controlled Trial (DEX-NEURO Trial)","DEX-NEURO","Inclusion Criteria:\n\n* All adult (American Society of Anaesthesiologists (ASA 1-2) who \\>18 years old and \\\u003C65 years old undergoing elective craniotomy\n\nExclusion Criteria:\n\n* Patients who are ASA 3-5 or BMI \\\u003C18\u002F \\>40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.","65 Years",{"count":55,"type":20},60,"INTERVENTIONAL",[58],"NA","Post-craniotomy pain is common and often undertreated. Inadequate analgesia can lead to patient discomfort and higher opioid consumption, which may result in respiratory depression, sedation risks and impaired neurological assessment in the early postoperative period. The incidence of post-operative delirium after intracranial surgery was 19%, ranging from 12 to 26% caused by variation in clinical features and delirium assessment methods1. It is associated with increased morbidity, longer length of hospital stay, and harm to self or staffs.\n\nDexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant respiratory depression. Most of the trials administered a loading dose of 0.5-1.0 μg\u002Fkg intravenous dexmedetomidine over 10 minutes followed by infusion dose 0.2-0.7 μg\u002Fkg\u002Fhour. The use of intraoperative dexmedetomidine is believed to reduce the usage of postoperative opioids where frequent neurological assessment is often required in neurosurgical patients. Beyond the benefit of analgesia, perioperative dexmedetomidine has been studied for prevention of postoperative delirium. Randomized trials in mixed noncardiac surgical populations reported that low-dose perioperative dexmedetomidine may reduce the incidence of delirium. Dexmedetomidine produces dose-dependent bradycardia and hypotension, which should be carefully monitored to maintain the cerebral perfusion pressure in brain surgery. However, most trials and meta-analyses have focused on general surgical or cardiac cohorts; the evidence remains limited in neurosurgical (craniotomy) patients.\n\nAlthough it showed promising benefits of analgesia and neuroprotection in non-neurosurgical patients, recent meta-analyses of intraoperative dexmedetomidine reported high degree of heterogeneity due to the inclusion of varied procedures (elective vs emergent craniotomy), dosing regimes (loading dose only versus loading dose + infusion versus infusion only) and varied primary endpoints (postoperative pain scores, cumulative opioid consumption or incidence of delirium). Therefore, this randomized, double-blind, placebo-controlled trial is designed to examine the use of intravenous dexmedetomidine in the reduction of postoperative pain score and delirium in neurosurgical patients. We hypothesised that intravenous dexmedetomidine reduces postoperative pain score and delirium with lower need of rescue analgesia and amount of morphine consumption in patients undergoing craniotomy.",[24,61,62],"Brain Cancer","Meningioma",[64,65,66,67,68],"dexmedetomidine","precedex","neurosurgery","delirium","pain","2026-02-02",{"date":71,"type":36},"2026-02-09",{"date":73,"type":20},"2026-07-22",{"date":75,"type":20},"2027-08-22",{"name":77,"class":78},"University of Malaya","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100390345","study-of-post-anesthesia-management-in-patients-undergoing-neurosurgery-100390345","NCT04362709","Study of Post-anesthesia Management in Patients Undergoing Neurosurgery","A Prospective Cohort Study of Post-anesthesia Management in Patients Undergoing Neurosurgery","Inclusion Criteria:\n\n* Patients received neurosurgery in Beijing Tiantan hospital.\n\nExclusion Criteria:\n\n* Preoperative severe cognitive dysfunction ；\n* Refused to sign informed consent.",{"count":87,"type":20},10000,"3 Years","The postoperative complications of neurosurgery are various and complex, which brings heavy economic and social burden to families. Timely detection and early intervention can help reduce the incidence of adverse events and mortality. The main purpose of this study is to analyze the possible factors related to postoperative complications of Neurosurgery, so as to achieve the prospective prevention and treatment of postoperative complications of neurosurgery.",[91,24,92],"Anesthesia","Complication","RECRUITING","2025-07-17",{"date":96,"type":36},"2025-07-18",{"date":98,"type":36},"2019-12-02",{"date":100,"type":20},"2028-11-22",{"name":102,"class":78},"Beijing Tiantan Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":56,"phases":114,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100596507","phase-4-remimazolam-and-emergence-delirium-in-pediatrics-100596507","NCT07046364","Remimazolam and Emergence Delirium in Pediatrics","The Effect of Remimazolam on Emergence Delirium in Pediatrics Undergoing Neurosurgery With Sevoflurane Anesthesia","Inclusion Criteria:\n\n* Aged 1 to 6 years old\n* Planned to receive elective neurosurgery under general anesthesia\n* Expected duration of surgery \\> 1 hour\n\nExclusion Criteria:\n\n* Allergy to benzodiazepine\n* Use of other sedatives within 12 hours before surgery such as benzodiazepines, propofol, chloral hydrate, etc.,\n* ASA classification IV or above\n* Unable to complete emergence delirium assessment, such as language, hearing or vision impairment.","1 Year","6 Years",{"count":113,"type":20},248,[115],"PHASE4","Emergence delirium is a common complication in pediatrics undergoing neurosurgery. Previous study showed that a single bolus of remimazolam was associated with lower incidence of postoperative agitation. Present study was designed to investigate if remimazolam supplemented to sevoflurane anesthesia could decrease the risk of emergence delirium in pediatrics undergoing neurosurgery.",[118,24,119,120,121],"Pediatric","Sevoflurane Anesthesia","Remimazolam","Emergence Delirium",[123,124,125,66,126],"emergence delirium","remimazolam","pediatric","sevoflurane anesthesia","2025-06-28",{"date":129,"type":36},"2025-07-01",{"date":131,"type":36},"2025-01-01",{"date":133,"type":20},"2027-01-01",{"name":135,"class":78},"Peking University First Hospital",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":21,"phases":4,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":136},"100584813","electroencephalogram-predicts-post-operative-delirium-100584813","NCT06894238","Electroencephalogram Predicts Post-operative Delirium","Frontal-temporal EEG During Anesthesia Recovery Predicts Postoperative Delirium in Neurosurgery: a Single-center, Prospective, Observational Study","EPOD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned elective neurosurgical surgery\n* ASA physical status I-II\n* Signed informed consent\n\nExclusion Criteria:\n\n* Known neurological or psychiatric disorders (e.g., epilepsy, Parkinson's disease)\n* Preoperative cognitive impairment (MMSE score \\\u003C 24)\n* Long-term use of central nervous system drugs (e.g., antidepressants, antipsychotics)\n* Language barriers\n* History of craniotomy within the last 12 months\n* Inability to place frontal-temporal electrodes due to conditions such as frontal skin injury, severe agitation, or a coronal incision for surgery\n* Pregnant or breastfeeding women",{"count":146,"type":20},137,"30 Days","The goal of this observational study is to investigate the predictive value of sub-hairline electroencephalography (EEG) during anesthesia recovery for postoperative delirium (POD). The main question to be answered is:\n\n* Can sub-hairline EEG measured during anesthesia recovery serve as a reliable predictor of POD? Adult patients undergoing elective craniotomy and admitted to the ICU will be enrolled. Sub-hairline EEG will be monitored until ICU discharge.",[24,150,26],"Delirium - Postoperative",[152,153,154,155,156,157,158],"Postoperative delirium","electroencephalography","neurosurgical patients","Sub-hairline EEG","Confusion Assessment Method for ICU (CAM-ICU)","Delirium Observation Screening Scale (DOSS)","Fluctuating Mental Status Evaluation (FMSE)","2025-03-18",{"date":161,"type":36},"2025-03-25",{"date":163,"type":36},"2025-03-01",{"date":165,"type":20},"2026-05-01",{"name":167,"class":78},"Beijing Sanbo Brain Hospital",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":56,"phases":179,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":136},"100502598","early-phase-1-testing-the-feasibility-of-using-ropivacaine-in-spinal-anesthesia-for-patients-with-lower-back-surgery-100502598","NCT05824338","Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery","SASS","Inclusion Criteria:\n\n* Adult patients who are equal to or greater than 18 years old\n* Undergoing elective one or two-level lumbar surgery via posterior surgical approach in the prone position (between L2-S1)\n* Expected surgery duration of no greater than 2 hours\n* ASA Physical Status Class 1 to 3\n* Patient can have either spinal anesthesia or general anesthesia\n* Able to provide consent and understand information in English, and capable of answering questions in English\n\nExclusion Criteria:\n\n* Allergy to either ropivacaine, bupivacaine, or local anesthetics\n* Contraindications to spinal anesthesia (i.e. coagulopathy or on anticoagulants, severe aortic or mitral valve stenosis, sepsis or bacteremia, thrombocytopenia, high intracranial pressure, infection at the puncture site)\n* Surgery is expected to take more than 2 hours\n* Emergency surgery\n* Previously had back surgery at the level of the spine currently being operated on\n* Comorbidities that require the patient to undergo general anesthesia\n* Inability to stay still during the surgery\n* Inability to move legs preoperatively\n* Body Mass Index (BMI) \\>35\n* Multilevel severe spinal stenosis","19 Years","80 Years",{"count":178,"type":20},45,[180],"EARLY_PHASE1","The goal of this pilot clinical trial is to test the feasibility of conducting a randomized controlled trial that will examine the use of ropivacaine in the spinal anesthesia for patients undergoing elective 1- or 2-level lower spine surgery. This study aims to:\n\n* Determine the rates of eligibility, recruitment, consent, and attrition\n* Determine the acceptability among patients, surgeons, anesthesiologists, and nurses of doing spine surgery under spinal anesthesia\n* Gather preliminary data on outcomes relevant to a future dose-finding study\n\nParticipants will be randomized to one of three treatment groups:\n\n* General anesthesia with endotracheal tube\n* Spinal anesthesia with bupivacaine\n* Spinal anesthesia with ropivacaine",[183,24,184,185],"Anesthesia, Spinal","Ropivacaine","Bupivacaine",[91,187,188,189],"Spinal","Lumbar surgery","Lower back","2024-10-04",{"date":192,"type":36},"2024-10-08",{"date":194,"type":36},"2024-08-27",{"date":196,"type":20},"2025-12-31",{"name":198,"class":78},"Fraser Health",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":56,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":44},"100547579","electrocorticographic-monitoring-of-brain-retraction-injury-embri-100547579","NCT06409806","Electrocorticographic Monitoring of Brain Retraction Injury (EMBRI)","Electrocorticography As a Neurophysiological Marker for Intraoperative Monitoring for Brain Retraction: an IDEAL Stage 1 Study","EMBRI","Inclusion Criteria:\n\n* Patients aged 16 or older undergoing intracranial surgery where it is anticipated fixed brain retraction will be used.\n\nExclusion Criteria:\n\n* Patients without capacity to give consent at time of recruitment","16 Years",{"count":209,"type":20},6,[58],"A single centre IDEAL Stage 1 feasibility study using novel electrophysiological recording techniques in adult participants undergoing neurosurgery. This is a first in human study, building upon previous preclinical mice experiments.\n\nParticipants will undergo their planned neurosurgical procedure as normal. In addition to their standard treatment neurophysiological monitoring including an electrocorticography electrode placed on the brain deep to the retractor will be used to monitor for signs of brain retraction injury.",[213,24,214],"Brain Injury","Brain Ischemia",[216],"Brain retraction","2024-09-17",{"date":219,"type":36},"2024-09-19",{"date":221,"type":36},"2022-08-01",{"date":223,"type":20},"2026-03-01",{"name":225,"class":78},"University College, London"]